Evaluation of 99mTc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT

Nuclear Medicine and Biology

Volumn 42, Issue 3, 2015, Pages 256-262

  Li, Fei ^a   Cheng, Teng ^a   Dong, Qingjian ^a   Wei, Rui ^a   Zhang, Zhenzhong ^a   Luo, Danfeng ^a   Ma, Xiangyi ^a   Wang, Shixuan ^a   Gao, Qinglei ^a   Ma, Ding ^a   Zhu, Xiaohua ^a   Xi, Ling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

99mTc HYNIC TMTP1; Metastasis; Ovarian cancer; SPECT imaging; TMTP1; Tumor imaging

Indexed keywords

HYNIC TMTP1 TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 6-HYDRAZINOPYRIDINE-3-CARBOXYLIC ACID; ASPARAGYL-VALYL-VALYL-ARGINYL-GLUTAMINE; HYDRAZINE DERIVATIVE; NICOTINIC ACID DERIVATIVE; OLIGOPEPTIDE; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; CONTROLLED STUDY; EX VIVO STUDY; GASTRIC CANCER CELL LINE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; METASTASIS; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; OVARY CANCER; PARTITION COEFFICIENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH CANCER; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; DRUG STABILITY; HUMAN; METABOLISM; PROCEDURES; RADIOCHEMISTRY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG STABILITY; HUMANS; HYDRAZINES; ISOTOPE LABELING; MICE; NEOPLASM METASTASIS; NICOTINIC ACIDS; OLIGOPEPTIDES; RADIOCHEMISTRY; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84922949539     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.11.001     Document Type: Article

References (34)

1. Loberg R.D., Bradley D.A., Tomlins S.A., Chinnaiyan A.M., Pienta K.J. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007, 57:225-241.
2. Riihimaki M., Thomsen H., Hemminki A., Sundquist K., Hemminki K. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 2013, 13:36.
3. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61:183-203.
4. Rockall A.G., Avril N., Lam R., Iannone R., Mozley P.D., Parkinson C., et al. Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. Clin Cancer Res 2014, 20:2751-2760.
5. Kyriazi S., Kaye S.B., deSouza N.M. Imaging ovarian cancer and peritoneal metastases-current and emerging techniques. Nature reviews. Clin Oncol 2010, 7:381-393.
6. Ebina Y., Watari H., Kaneuchi M., Takeda M., Hosaka M., Kudo M., et al. Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer. Eur J Nucl Med Mol Imaging 2014, 41:446-451.
7. Chen Y.M., Chen T., Zee C.S., Shi Y.P., Wan L.R., Tong L.J. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun 2014, 35:347-352.
8. Correia J.D., Paulo A., Raposinho P.D., Santos I. Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans 2011, 40:6144-6167.
9. Ambrosini V., Fani M., Fanti S., Forrer F., Maecke H.R. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011, 52(Suppl. 2):42S-55S.
10. Bach-Gansmo T., Danielsson R., Saracco A., Wilczek B., Bogsrud T.V., Fangberget A., et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. J Nucl Med 2006, 47:1434-1439.
11. Dijkgraaf I., Beer A.J., Wester H.J. Application of RGD-containing peptides as imaging probes for alphavbeta3 expression. Front Biosci 2009, 14:887-899.
12. Yang W., Luo D., Wang S., Wang R., Chen R., Liu Y., et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 2008, 14:5494-5502.
13. Liu R., Xi L., Luo D., Ma X., Yang W., Xi Y., et al. Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD. J Control Release 2012, 161:893-902.
14. Ma X., Lv P., Ye S., Zhang Y., Li S., Kan C., et al. DT390-triTMTP1, a novel fusion protein of diphtheria toxin with tandem repeat TMTP1 peptide, preferentially targets metastatic tumors. Mol Pharm 2013, 10:115-126.
15. Ma X.Y., Li S., Luo D.F., Liu R.H., Lu Y.P., Wang S.X., et al. Antitumor and antimetastatic effect of antimicrobial peptide conjugated with tumor homing peptide TMTP1 on the transplanted prostate cancer and gastric cancer in nude mice. Zhonghua Zhong Liu Za Zhi 2013, 35:737-741.
16. Ma X., Xi L., Luo D., Liu R., Li S., Liu Y., et al. Anti-tumor effects of the peptide TMTP1-GG-D(KLAKLAK)(2) on highly metastatic cancers. PLoS One 2012, 7:e42685.
17. Liu R., Ma X., Wang H., Xi Y., Qian M., Yang W., et al. The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases. J Mol Med 2014, 92:165-175.
18. Decristoforo C., Faintuch-Linkowski B., Rey A., von Guggenberg E., Rupprich M., Hernandez-Gonzales I., et al. 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol 2006, 33:945-952.
19. Gonzalez-Vazquez A., Ferro-Flores G. Arteaga de Murphy C, and Gutierrez-Garcia Z. Biokinetics and dosimetry in patients of 99mTc-EDDA/HYNIC-Tyr3-octreotide prepared from lyophilized kits. Appl Radiat Isot 2006, 64:792-797.
20. Ortiz-Arzate Z., Santos-Cuevas C.L., Ocampo-Garcia B.E., Ferro-Flores G., Garcia-Becerra R., Estrada G., et al. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging. Nucl Med Commun 2014, 35:423-432.
21. Liu Y., Lan X., Wu T., Lang J., Jin X., Sun X., et al. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor. Nucl Med Biol 2014, 41:450-456.
22. Ananias H.J., Yu Z., Dierckx R.A., van der Wiele C., Helfrich W., Wang F., et al. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm 2011, 8:1165-1173.
23. Li J., Liang S., Yu H., Zhang J., Ma D., Lu X. An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol 2010, 119:543-548.
24. Yu D., Wolf J.K., Scanlon M., Price J.E., Hung M.C. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993, 53:891-898.
25. Meszaros L.K., Dose A., Biagini S.C., Blower P.J. Synthesis and evaluation of analogues of HYNIC as bifunctional chelators for technetium. Dalton Trans 2011, 40:6260-6267.
26. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008, 60:1347-1370.
27. Liu S., He Z., Hsieh W.Y., Kim Y.S., Jiang Y. Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. Bioconjug Chem 2006, 17:1499-1507.
28. Vegt E., Melis M., Eek A., de Visser M., Brom M., Oyen W.J., et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011, 38:623-632.
29. Vegt E., van Eerd J.E., Eek A., Oyen W.J., Wetzels J.F., de Jong M., et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008, 49:1506-1511.
30. Vegt E., Eek A., Oyen W.J., de Jong M., Gotthardt M., Boerman O.C. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010, 37:226-234.
31. Gotthardt M., van Eerd-Vismale J., Oyen W.J.G., de Jong M., Zhang H., Rolleman E., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007, 48:596-601.
32. Fung S., Hruby V.J. Design of cyclic and other templates for potent and selective peptide alpha-MSH analogues. Curr Opin Chem Biol 2005, 9:352-358.
33. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 1999, 42:3033-3040.
34. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009, 20:2199-2213.